Table 2.
Representative ongoing clinic trials of CAR-T therapy for treating solid tumors.
| Target Antigen | Disease | CAR Generation | Delivery Route | Clinical Phase | Clinical Trials Identifier |
|---|---|---|---|---|---|
| CEA | Liver metastasis | Unspecified Unspecified Second |
Hepatic Artery Hepatic Artery Hepatic Artery |
I I I |
NCT02416466 NCT02850536 NCT03818165 |
| CEA | Malignant ascites | Unspecified | Intraperitoneal | I | NCT03682744 |
| LeY | Advanced cancer | Second | Intravenous | I | NCT03851146 |
| EGFRvIII | Glioblastoma | Second | Intracerebroventricular | I | NCT05063682 |
| CCT301 | Renal cell carcinoma | Unspecified | Intravenous | II | NCT03393936 |
| Glypican-3 | Advanced hepatocellular carcinoma | Fourth Unspecified |
Intravenous Unspecified |
I I |
NCT03980288 NCT02395250 |
| GD2 | Sarcoma | Third | Intravenous | I | NCT02107963 |
| HER2 | Sarcoma | Second | Intravenous | I | NCT00902044 |
| PSMA | Metastatic castration-resistant prostate cancer | Unspecified | Intravenous | I | NCT04227275 |
| MUC1 | Metastatic breast cancer | Second | Intravenous | I | NCT04020575 |
| ROR1 | ROR1+ neoplasm | Third | Intravenous | I | NCT02706392 |
| Mesothelin | Pancreatic adenocarcinoma | Unspecified | Intravenous, Intraperitoneal, and Intrahepatic infusion | I | NCT03323944 |
| Claudin 18.2 | Advanced gastric adenocarcinoma | Second | Intravenous | I | NCT03159819 |